TP53 mutation is related to poor prognosis after radiotherapy, but not surgery, in squamous cell carcinoma of the head and neck.
METHODS
TP53 gene-mutation and expression of p53 have been described to influence the radiosensitivity of tumour cells from head and neck carcinomas. The present study was performed to evaluate whether TP53 mutation may influence the clinical outcome of head and neck cancer patients treated with radiotherapy or surgery.


METHODS
DNA was extracted from formalin-fixed paraffin-embedded tissue sections from primary biopsies taken before radiotherapy. Gene mutations (in exons 5-9) were identified using denaturing gradient gel electrophoresis (DGGE) as the initial scanning procedure and characterized by sequencing. Patients were treated with primary radiotherapy or surgery alone. Treatment was given according to the DAHANCA schedules with 5 or 6 weekly fractions (2 Gy) of radiotherapy (66-68 Gy). Most patients were also treated with the hypoxic radiosensitizer Nimorazole. The results are reported as 5-year actuarial values, and differences estimated by log-rank analysis.


RESULTS
The present analysis is based on 114 patients with squamous cell carcinoma of the larynx, pharynx and oral cavity diagnosed between March 1992 and October 1996. Ninety patients received primary radiotherapy alone and 21 were treated with surgery. TP53 mutations were found in 45 patients (39%) and in patients receiving radiotherapy, TP53 mutation was highly associated with poor prognosis. Loco-regional control rates (5-year actuarial values) for TP53 mutation was 29 vs. 54% for TP53 wildtype (P < 0.01). For disease-free survival the corresponding values were 13 and 38% (P < 0.01), respectively. The correlations were not found to be related to specific subtypes of mutations (e.g. missense mutations affecting DNA-contact or Zn-binding regions) but rather to the presence of any mutation at all. In contrast, TP53 mutation did not influence the response to surgery.


CONCLUSIONS
A strong relationship was observed between TP53 mutation and poor prognosis (increased risk of loco-regional failure and death) in head and neck cancer patients given primary radiotherapy but not surgery.
Alsner
J
J
Department of Experimental Clinical Oncology, Aarhus University Hospital, Noerrebrogade 44, Building 5, 8000, Aarhus C, Denmark.
Sørensen
S B
SB
Overgaard
J
J
D002294:Carcinoma, Squamous Cell / Q000235:genetics / Q000532:radiotherapy* / Q000601:surgery*; D016009:Chi-Square Distribution; D005260:Female; D016158:Genes, p53 / Q000235:genetics*; D006258:Head and Neck Neoplasms / Q000235:genetics / Q000532:radiotherapy* / Q000601:surgery*; D006801:Humans; D007822:Laryngeal Neoplasms / Q000235:genetics / Q000532:radiotherapy / Q000601:surgery; D008297:Male; D009062:Mouth Neoplasms / Q000235:genetics / Q000532:radiotherapy / Q000601:surgery; D015999:Multivariate Analysis; D009154:Mutation / Q000235:genetics*; D010610:Pharyngeal Neoplasms / Q000235:genetics / Q000532:radiotherapy / Q000601:surgery; D011379:Prognosis; D016016:Proportional Hazards Models; D016019:Survival Analysis; D016896:Treatment Outcome